Yun Gregan
Merck & Co.
8 Papers
93 Citations
Yun Gregan is an academic researcher from Merck & Co.. The author has contributed to research in topics: Internal medicine & Belimumab. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).
Craig A. Coburn,Yunfu Luo,Mingxiang Cui,Jiabing Wang,Richard Soll,Jingchao Dong,Bin Hu,Michael A. Lyon,Vincent P. Santarelli,Richard L. Kraus,Yun Gregan,Yi Wang,Steven V. Fox,Jacquelyn Binns,Scott M. Doran,Duane R. Reiss,Pamela L. Tannenbaum,Anthony L. Gotter,Peter T. Meinke,John J. Renger +19 more
TL;DR: The discovery and lead optimization efforts for a novel series of TASK‐3 channel antagonists based on a 5,6,7,8‐tetrahydropyrido[4,3‐d]pyrimidine high‐throughput screening lead from which a subseries of potent and selective inhibitors were identified were described.
64
Benzoxazolinone aryl sulfonamides as potent, selective Na v 1.7 inhibitors with in vivo efficacy in a preclinical pain model
Joseph E. Pero,Michael A. Rossi,Hannah D. G. F. Lehman,Michael J. Kelly,James Mulhearn,Scott E. Wolkenberg,Matthew J. Cato,Michelle K. Clements,Christopher Daley,Tracey Filzen,Eleftheria N. Finger,Yun Gregan,Darrell A. Henze,Aneta Jovanovska,Rebecca M. Klein,Richard L. Kraus,Yuxing Li,Annie Liang,John Majercak,Jacqueline Panigel,Mark O. Urban,Jixin Wang,Ying-Hong Wang,Andrea K. Houghton,Mark E. Layton +24 more
TL;DR: Novel, peripherally-restricted benzoxazolinone aryl sulfonamides are reported as potentNav1.7 inhibitors with excellent selectivity against the Nav1.5 isoform, which is expressed in the heart muscle.
33
Op0281 pharmacodynamic effect of sequential belimumab (bel) and rituximab (rtx) therapy in patients (pts) with systemic lupus erythematosus (sle): the phase 3, randomised, placebo-controlled bliss-believe study
Y K Onno Teng,A Van Maurik,Keith L. Clark,N. L. Fox,Yun Gregan,J. Groark,R. Henderson,Josephine Ocran-Appiah,David M. Roth,Don N Shanahan,Paul P. Tak,Cynthia Aranow +11 more
TL;DR: Repopulation of total CD19+ B cells and most B-cell subsets towards BL levels by Wk 104 was most evident with BEL/RTX, while low circulating CD20+CD27+ memory B cell levels remained relatively unchanged (Table 1).
Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.
E J Arends,Mihaela Zlei,Christopher M. Tipton,J. Cotic,Zgjim Osmani,Fenna J de Bie,Sylvia W.A. Kamerling,Andre van Maurik,Richard Dimelow,Yun Gregan,Norma Lynn Fox,Ton J. Rabelink,David A Roth,Ignacio Sanz,Jacques J. M. van Dongen,C. van Kooten,Y. K. O. Teng +16 more
TL;DR: Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus results in a non-proliferating, de-activated MBC population.
2
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
Jacob N Hunnicutt,Jolyon Fairburn-Beech,M. E. Georgiou,A. Richards,Yun Gregan,Holly Quasny,D. Chauhan +6 more
TL;DR: In this paper , the authors used data from the US evaluation of use of Belimumab in clinical practice SEttings (OBSErve) study (GSK Study 117295), an observational cohort study of adults with SLE initiating and continuing belimumab for ≥6 months.